Perfan (enoximone) / Sanofi - LARVOL DELTA

Administration of Enoximone for the Optimisation of Renal Function in Cardiac Surgery: Final Results of a Multicentre Study. (PubMed, Heart Lung Circ) - "Perioperative enoximone administration was associated with improved renal function and reduced hospital length of stay in patients undergoing on-pump cardiac surgery. These findings support its potential role in preventing postoperative renal failure. Further studies are warranted to confirm these results."

Journal • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease

Ventricle-Specific Biomechanical Responses to Inotropic and Vasoactive Drugs in Human Myocardial Slices. (PubMed, J Cardiovasc Transl Res) - "This study aimed to compare baseline biomechanical contractile properties between right (RV) and left ventricular (LV) human living myocardial slices (LMS) and explore the effect of dobutamine, noradrenaline, adrenaline, levosimendan and enoximone in both ventricles. In conclusion, RV LMS showed a stronger contraction with higher contraction velocity as compared to LV LMS and exhibited a greater response to dobutamine. These findings contribute to the understanding of the RV physiology as a separate entity, advocating for a different approach in treating RV or LV dysfunction."

Clinical • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Statement of Retraction: Combined use of ultra-short acting β-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone. (PubMed, Expert Opin Pharmacother) - No abstract available

Journal

Clinical Importance of Phosphodiesterase 3 Inhibitors on Outcomes in Patients With Cardiogenic Shock　- A Systematic Review. (PubMed, Circ Rep) - "One RCT compared milrinone with dobutamine (DOB), and another compared enoximone with levosimendan. Meta-analysis revealed that PDE3i were neither superior nor inferior for the outcomes in the total cohort (odds ratio [OR] 1.47, 95% confidence interval [CI] 0.35-6.26 for early deaths; OR 1.14, 95% CI 0.42-3.14 for cardiac arrest; OR 1.53, 95% CI 0.80-2.92 for the initiation of renal replacement therapy). The present systematic review revealed no difference in outcomes, early deaths, cardiac arrest and initiation of renal replacement therapy when using PDE3i in patients with CS treated with or without other inotropes."

Journal • Cardiovascular

Retraction Note: Der neue Phosphodiesterasehemmer Enoximone: Einsatzmöglichkeiten im Rahmen herzchirurgischer Eingriffe. (PubMed, Herz) - No abstract available

Journal

Routine administration of enoximone in neonates and infants undergoing cardiac surgery with cardiopulmonary bypass to prevent and treat early low cardiac output syndrome. (PubMed, Br J Anaesth) - No abstract available

Journal • Cardiovascular • Pediatrics

First Results of Our Local Practice Guide Used During the Late Phase of Resuscitation in Patients with Refractory VF in Out of Hospital Cardiac Arrest. (PubMed, Open Access Emerg Med) - "This local practice HEMS treatment algorithm consisted of, among others, cessation of epinephrine and alternating administration of esmolol and norepinephrine combined with enoximone. In patients with persisting VF despite prolonged advanced life support care, a multifaceted bundle of care approach shows promising results and warrants further research. Alternative drug administrations were found to be substantially easier to achieve compared to alternative defibrillation positions."

Journal • Cardiovascular

Assessing institutional responsibility in scientific misconduct: A case study of enoximone research by Joachim Boldt. (PubMed, Clin Trials) - "The current guidelines of the Committee on Publication Ethics for retraction are inadequate for large-scale scientific misconduct. Comprehensive ethics training, regular audits, and transparent reporting are essential to ensure the credibility of published research."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review. (PubMed, Eur Cardiol) - "By synthesising evidence from numerous studies, a comparison of levosimendan over traditional inotropic agents, such as enoximone, dobutamine, dopamine and norepinephrine, is highlighted. Safety profiles and adverse effects are critically assessed to provide a balanced view of the therapeutic window provided by levosimendan. The review concludes that levosimendan is a valuable addition to the therapeutic strategy against CS, with the potential to improve patient outcomes."

Journal • Review • Cardiovascular

Aerosol of Enoximone/Hydroxypropyl-β-Cyclodextrin Inclusion Complex, Biopharmaceutical Evidence for ARDS Applicability. (PubMed, Pharmaceutics) - "This study offers a promising advance in the optimization of enoximone delivery to the lungs."

Journal • Acute Respiratory Distress Syndrome • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Enoximone alleviates atopic dermatitis-like skin inflammation via inhibition of type 2 T helper cell development. (PubMed, Int Immunopharmacol) - "Collectively, the results demonstrate that Enox alleviates AD-like skin inflammation by inhibiting T-cell development. Thus, Enox may be a therapeutic candidate for the treatment of AD."

Journal • Allergy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • GATA3

Cyclic nucleotide phosphodiesterases: therapeutic targets in cardiac hypertrophy and failure (PubMed, Med Sci (Paris)) - "Although PDE3 inhibitors such as milrinone or enoximone can be used clinically to improve systolic function and relieve the symptoms of acute CHF, their chronic use has proved detrimental. In this review, we describe cAMP and cGMP signalling in cardiomyocytes and present the different families of PDEs expressed in the heart and their modifications in pathological cardiac hypertrophy and HF. We also review results from preclinical models and clinical data indicating the use of specific PDE inhibitors or activators that may have therapeutic potential in CI."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

UNLOAD-HF: Unloading in Heart Failure Cardiogenic Shock (clinicaltrials.gov) - P=N/A | N=456 | Not yet recruiting | Sponsor: Amsterdam UMC, location VUmc | Trial completion date: Dec 2026 ➔ Jul 2028 | Trial primary completion date: Feb 2026 ➔ Oct 2027

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

A plea for personalization of the hemodynamic management of septic shock. (PubMed, Crit Care) - "Based on pharmacologic properties, we suggest as the first test a limited dose of dobutamine, to add enoximone or milrinone in the second line and substitute or add levosimendan if inefficient. Regarding adjunctive therapies, while hydrocortisone is nowadays advised in patients receiving high doses of vasopressors, patients responding to corticosteroids may be identified in the future by the analysis of selected cytokines or specific transcriptomic endotypes. To conclude, although some general rules apply for shock management, a personalized approach should be considered for hemodynamic monitoring and support."

Journal • Review • Septic Shock

Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure. (PubMed, Nat Rev Cardiol) - "Although PDE3 inhibitors, such as milrinone or enoximone, have been used clinically to improve systolic function and alleviate the symptoms of acute HF, their chronic use has proved to be detrimental. In this Review, we describe cAMP and cGMP signalling in cardiomyocytes and present the various PDE families expressed in the heart as well as their modifications in pathological cardiac hypertrophy and HF. We also appraise the evidence from preclinical models as well as clinical data pointing to the use of inhibitors or activators of specific PDEs that could have therapeutic potential in HF."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

The Effects of Enoximone in Acute Exacerbation COPD (clinicaltrials.gov) - P4; N=3; Terminated; Sponsor: Rijnstate Hospital; N=15 ➔ 3; Trial completion date: Mar 2021 ➔ Dec 2021; Not yet recruiting ➔ Terminated; Trial primary completion date: Mar 2021 ➔ Dec 2021; A limited number of inclusions due to the Covid-pandemic

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

UNLOAD-HF: Mechanical Left Ventricular Unloading in Acute Decompensated Heart Failure (clinicaltrials.gov) - P=N/A; N=456; Not yet recruiting; Sponsor: VU University Medical Center; Initiation date: Dec 2021 ➔ Jun 2022

Trial initiation date • Cardiovascular • Congestive Heart Failure • Heart Failure

Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report. (PubMed, Can Respir J) - "The evaluation shows that PDE3-inhibitor enoximone is a viable alternative for or addition to current asthma therapeutics, as both add-on and stand-alone, considerably reducing the use of LABAs/SABAs/ICS, with no or negligible side effects. Additional studies are advisable."

Clinical • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

UNLOAD-HF: Mechanical Left Ventricular Unloading in Acute Decompensated Heart Failure (clinicaltrials.gov) - P=N/A; N=456; Not yet recruiting; Sponsor: VU University Medical Center

New trial • Cardiovascular • Congestive Heart Failure • Heart Failure

MULTIFACETED APPROACH FOR DESENSITIZATION OF A HYPERIMMUNE HEART TRANSPLANTATION RECIPIENT (ESOT 2021) - "She was treated with intravenous inotropic drugs (enoximone 2-2.5 mcg/kg/min), improving clinical status and, after 8 days, entered in macro-area urgency (level 2) due to the difficulty of allocation due to elevated class II PRA. Due to the sliding on inotropic support state, the patient underwent immunoadsorption (IA) (five sessions) and started rituximab (4 doses in two weeks), resulting in a 5% reduction of PRA...Pre-discharge extracorporeal photopheresis (ECP) has been started; she was discharged at home in good clinical conditions and is now in follow-up from 3 months. Intriguingly, after ECP the Donor-Specific Antibody titer abruptly decreased."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hepatology • Hypertrophic Cardiomyopathy • Infectious Disease • Liver Failure • Septic Shock • Transplantation • Ventricular Tachycardia

Phosphodiesterase-3 Inhibitor Enoximone in SARS-CoV-2 Infection. (PubMed, J Aerosol Med Pulm Drug Deliv) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Vasoactive pharmacologic therapy in cardiogenic shock: a critical review. (PubMed, J Drug Assess) - "The studies evaluated the comparisons of norepinephrine (NE) vs. dopamine, epinephrine vs. NE, levosimendan vs. dobutamine, enoximone or placebo, and nitric oxide synthase inhibitors (NOSi) vs. placebo. The methodological quality between the studies is variable due to the inherent difficulties to conduct a study in CS. Vasopressors and inotropes continue to have a fundamental role given the lack of pharmacological alternatives."

Journal • Review • Cardiovascular • Myocardial Infarction

The Potential Role of Aerosolized Phosphodiesterase 3 Inhibitor Enoximone in the Management of Coronavirus Disease 2019 Hypoxemia: A Case Report. (PubMed, J Aerosol Med Pulm Drug Deliv) - "Intravenous infusions of phosphodiesterase inhibitors are commonly used as pulmonary vasodilators in the management of pulmonary hypertension. This is the first case showing that inhaled route administration of PDE3 inhibitor enoximone could be important in the management of COVID-19 hypoxemia, to restore perfusion in noninjured part of the lung, improving oxygenation and avoiding risks of systemic infusion."

Clinical • Journal • Hypertension • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Post-transplant Inotrope Score is Associated with Clinical Outcomes after Adult Heart Transplantation. (PubMed, Clin Transplant) - "High inotrope score post-HTx was observed in recipient congenital heart disease and was associated with a higher risk of mortality and acute kidney injury."

Clinical • Clinical data • Journal • Acute Kidney Injury • Cardiovascular • Heart Failure • Nephrology • Renal Disease • Transplantation • CRP

PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia. (PubMed, Exp Lung Res) - "Our preliminary observations suggest that early intervention with the selective PDE3-inhibitor enoximone may help to revert respiratory failure as well as avert mechanical ventilation, and reduces ICU/hospital time in patients with severe SARS-CoV-2 pneumonia. Our findings warrant further research on the therapeutic potential of PDE3-inhibition, alone or in combination with other anti-COVID-19 strategies."

Clinical • Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases